DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Parnate is a drug marketed by Concordia and is included in one NDA.
The generic ingredient in PARNATE is tranylcypromine sulfate. There are six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the tranylcypromine sulfate profile page.
A generic version of PARNATE was approved as tranylcypromine sulfate by PAR PHARM on June 29th, 2006.
Recent Clinical Trials for PARNATE
Identify potential brand extensions & 505(b)(2) entrants
|Central Michigan University||N/A|
|Sheppard Pratt Health System||N/A|
|National Institute of Mental Health (NIMH)||Phase 4|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Concordia||PARNATE||tranylcypromine sulfate||TABLET;ORAL||012342-003||Aug 16, 1985||AB||RX||Yes||Yes||Start Trial||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|